G007-LK Tankyrase 1/2 Inhibitor: Precision Tool for Wnt/β-Catenin and APC-Mutant Cancer Research

Executive Summary: G007-LK is a highly selective small-molecule inhibitor targeting tankyrase 1 (TNKS1) and tankyrase 2 (TNKS2), both key regulators of Wnt/β-catenin signaling and cell proliferation (Jia et al., 2017, https://doi.org/10.1371/journal.pone.0184068). The compound exhibits IC₅₀ values of 46 nM (TNKS1) and 25 nM (TNKS2) in biochemical assays, demonstrating robust potency. In APC-mutant colorectal cancer cell lines, G007-LK induces β-catenin degradation via degradasome formation, reducing tumor growth in mouse xenograft models. As a tool compound, its utility extends to Hippo pathway modulation and YAP inhibition. APExBIO supplies G007-LK (SKU B5830) with validated specifications for research use (https://www.apexbt.com/g007-lk.html).

Biological Rationale

Tankyrases (TNKS1 and TNKS2) are poly(ADP-ribosyl) polymerases (PARPs) that regulate protein homeostasis, Wnt/β-catenin signaling, telomere maintenance, and cell cycle progression (Jia et al., 2017). In cancer, aberrant Wnt/β-catenin signaling—often driven by APC mutations—promotes β-catenin accumulation and transcription of oncogenic targets. TNKS1/2 activity leads to poly(ADP-ribosyl)ation and subsequent degradation of AXIN, a negative Wnt regulator. Inhibition of tankyrases stabilizes AXIN1/2, facilitating β-catenin degradation and Wnt pathway suppression. Targeting tankyrases is therefore a rational strategy for controlling Wnt-driven tumorigenesis and modulating Hippo/YAP signaling.

Mechanism of Action of G007-LK tankyrase 1/2 inhibitor

G007-LK is a small-molecule inhibitor with a molecular weight of 529.96 Da and chemical formula C₂₅H₁₆ClN₇O₃S (APExBIO product page). It selectively inhibits TNKS1/2 by binding the PARP catalytic domain, blocking auto-poly(ADP ribosyl)ation. This results in AXIN1/2 stabilization and subsequent assembly of 'degradasomes'—multi-protein complexes containing phosphorylated β-catenin, β-TrCP, and ubiquitin. Degradasome formation triggers proteasomal degradation of β-catenin, suppressing Wnt/β-catenin transcriptional output. In cell models, G007-LK inhibits Wnt3a-induced ST-Luc reporter activity with an IC₅₀ of 0.05 μM. In hepatocellular carcinoma and colorectal cancer cell lines, this leads to decreased YAP protein levels and reduced YAP/TEAD signaling (Jia et al., 2017).

Evidence & Benchmarks

• G007-LK inhibits TNKS1 auto-poly(ADP ribosyl)ation with an IC₅₀ of 46 nM and TNKS2 at 25 nM, in enzymatic assays (APExBIO).
• Suppresses Wnt3a-induced ST-Luc reporter activity in HEK 293 cells with an IC₅₀ of 0.05 μM (APExBIO).
• Induces degradasome formation and β-catenin degradation in APC-mutant SW480 colorectal cancer cells (Jia et al., 2017, DOI).
• Reduces tumor growth and β-catenin levels in COLO-320DM xenograft mouse models at 20–40 mg/kg dosing (APExBIO).
• Stabilizes AXIN1/2 and upregulates Angiomotin-like 1/2 (AMOTL1/2), suppressing YAP/TAZ activity in hepatocellular carcinoma cells (Jia et al., 2017, DOI).

Compared to earlier articles such as "A Molecular Dissection of Wnt/β-Catenin Inhibition by G007-LK", this review expands on validated in vivo benchmarks and mechanistic links to Hippo/YAP modulation. For workflow challenges, see "Scenario-Driven G007-LK Use Cases"; this article focuses on atomic, cross-tumor evidence and pitfalls. Additionally, "G007-LK: Specific Tankyrase Inhibitor for Wnt Signaling Research" highlights assay reproducibility, while the current article details mechanistic selectivity and clinical translation boundaries.

Applications, Limits & Misconceptions

Applications:

• Dissection of Wnt/β-catenin signaling in APC-mutant colorectal cancer models.
• Study of Hippo/YAP pathway regulation via AMOTL1/2 stabilization.
• Cell cycle and colony formation assays in cancer research.
• In vivo tumor growth inhibition in xenograft models (20–40 mg/kg, mouse).
• Tool compound for mechanistic studies of poly(ADP-ribosyl)ation.

Limits:

• Not effective in cells lacking functional Wnt/β-catenin pathway or with β-catenin mutations that bypass degradation.
• Solubility constraints: soluble at ≥26.5 mg/mL in DMSO; insoluble in water and ethanol (APExBIO).
• Short-term solution stability; long-term storage at -20°C recommended.
• Does not directly inhibit non-tankyrase PARP family members.
• Not validated for therapeutic use in humans; for research only.

Common Pitfalls or Misconceptions

• Assuming efficacy in tumors driven by β-catenin mutations not susceptible to degradation—G007-LK targets pathways upstream of β-catenin stability.
• Using aqueous solvents—G007-LK is insoluble in water and ethanol, requiring DMSO for dissolution.
• Expecting direct inhibition of YAP/TAZ—YAP/TAZ suppression is indirect, mediated by AMOTL1/2 stabilization.
• Applying for clinical therapy—G007-LK is a research-use-only tool, not approved for human or veterinary treatment.
• Assuming pan-PARP inhibition—G007-LK is selective for tankyrase 1/2, not general PARPs.

Workflow Integration & Parameters

G007-LK (SKU B5830, APExBIO) is supplied as a solid and should be dissolved in DMSO to a stock concentration of ≥26.5 mg/mL. For cell-based assays, typical working concentrations range from 0.01 μM to 2 μM, depending on cell type and endpoint. For in vivo studies, dosing between 20–40 mg/kg (mouse, oral or intraperitoneal) has been shown to reduce tumor growth and β-catenin levels (APExBIO). Solutions are recommended for short-term use; store powder at -20°C with desiccant. Key readouts include β-catenin protein levels (Western blot), Wnt/β-catenin reporter activity, and cell proliferation or colony formation assays. For reproducibility, batch validation and parallel vehicle controls are essential. Inter-assay variation can be minimized by using standardized protocols as outlined in workflow resources (Scenario-Driven Use Cases).

Conclusion & Outlook

G007-LK is a robust, validated tankyrase 1/2 inhibitor for dissecting Wnt/β-catenin and Hippo/YAP signaling in APC-mutant and other cancer models. Its nanomolar potency, selectivity, and reproducibility have established it as a gold standard for research on β-catenin degradation and AXIN stabilization. While not a therapeutic, G007-LK accelerates discoveries in cancer biology and signal transduction. Future research may explore its role in combinatorial drug strategies and in elucidating resistance mechanisms. For detailed specifications or to order, see the G007-LK tankyrase 1/2 inhibitor product page (APExBIO).